Although both in vitro and in vivo studies have proven that lumacaftor can improve the maturation and function of the F508del CFTR protein [68, 121], lumacaftor monotherapy has shown insufficient clinical benefits in CF adults who are homozygous for the F508del CFTR, despite a moderate but significant reduction in sweat chloride [67]. This evidence concerns the gene CFTR and cystic fibrosis.